Maria G. Morritti
San Giovanni Rotondo, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy.
Journal: Frontiers in oncology
Published: March 30, 2026
Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study.
Journal: Breast cancer research and treatment
Published: March 26, 2026
BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.
Journal: Journal of clinical medicine
Published: November 12, 2025
Impact of Chemotherapy Dose Intensity on Pathological Complete Response in Pembrolizumab-Treated Early Triple-Negative Breast Cancer: A Real-World Multicenter Analysis.
Journal: Cancers
Published: September 18, 2025
Development of a microRNA-based prognostic model for accurate prediction of distant metastasis in breast cancer patients.
Journal: Breast cancer research : BCR
Published: March 17, 2025
Tumor Suppressor miR-27a-5p and Its Significance for Breast Cancer.
Journal: Biomedicines
Published: October 23, 2024
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial.
Journal: Breast (Edinburgh, Scotland)
Published: January 06, 2024
Combined analysis of miR-200 family and its significance for breast cancer.
Journal: Scientific reports
Published: July 27, 2020
Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors.
Journal: Frontiers in oncology
Published: March 26, 2020
Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study.
Journal: Journal of geriatric oncology
Published: February 21, 2019
Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel.
Journal: Scientific reports
Published: February 21, 2019
Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study.
Journal: Future oncology (London, England)
Published: November 10, 2018
Last Updated: 09/26/2026